CWA Asset Management Group’s GSK GSK Stock Holding History

CWA Asset Management Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.78M	Buy	53,030 +6,089	+13%	+$322K	0.08%	227
2026 Q1	$2.59M	Buy	46,941 +5,995	+15%	+$325K	0.09%	219
2025 Q4	$2.01M	Buy	40,946 +5,671	+16%	+$264K	0.07%	229
2025 Q3	$1.52M	Buy	35,275 +4,566	+15%	+$178K	0.06%	277
2025 Q2	$1.18M	Buy	30,709 +8,595	+39%	+$328K	0.05%	303
2025 Q1	$857K	Buy	22,114 +5,904	+36%	+$216K	0.04%	323
2024 Q4	$548K	Sell	16,210 -30,397	-65%	-$1.09M	0.03%	367
2024 Q3	$1.91M	Buy	+46,607	New	+$1.91M	0.1%	160
2024 Q1	$1.01M	Sell	23,605 -1,249	-5%	-$51.5K	0.06%	222
2023 Q4	$921K	Sell	24,854 -478	-2%	-$17.2K	0.06%	175
2023 Q3	$918K	Buy	25,332 +1,372	+6%	+$48.7K	0.07%	152
2023 Q2	$854K	Buy	23,960 +755	+3%	+$27.1K	0.06%	154
2023 Q1	$826K	Buy	23,205 +3,358	+17%	+$117K	0.06%	145
2022 Q4	$697K	Buy	19,847 +1,027	+5%	+$34.2K	0.06%	160
2022 Q3	$554K	Buy	18,820 +825	+5%	+$31.3K	0.05%	159
2022 Q2	$979K	Buy	17,995 +603	+3%	+$33.3K	0.09%	122
2022 Q1	$947K	Buy	17,392 +4,780	+38%	+$260K	0.07%	131
2021 Q4	$695K	Hold	12,612	–	–	0.05%	157
2021 Q3	$602K	Sell	12,612 -380	-3%	-$19.1K	0.05%	165
2021 Q2	$652K	Buy	+12,992	New	+$624K	0.05%	156
2020 Q1	–	Sell	-4,954	Closed	-$291K	–	244
2019 Q4	$291K	Sell	4,954 -389	-7%	-$21.6K	0.05%	179
2019 Q3	$285K	Sell	5,343 -11	-0.2%	-$566	0.05%	171
2019 Q2	$268K	Sell	5,354 -30	-0.6%	-$1.5K	0.05%	181
2019 Q1	$281K	Sell	5,384 -304	-5%	-$15.2K	0.05%	166
2018 Q4	$272K	Buy	5,688 +1,020	+22%	+$50.2K	0.06%	160
2018 Q3	$234K	Sell	4,668 -744	-14%	-$37.8K	0.05%	177
2018 Q2	$273K	Sell	5,412 -350	-6%	-$17.6K	0.06%	159
2018 Q1	$280K	Buy	5,762 +1,200	+26%	+$55.9K	0.07%	147
2017 Q4	$202K	Hold	4,562	–	–	0.05%	164
2017 Q3	$232K	Buy	4,562 +216	+5%	+$11K	0.07%	146
2017 Q2	$234K	Sell	4,346 -710	-14%	-$37.9K	0.07%	141
2017 Q1	$266K	Buy	5,056 +600	+13%	+$30.4K	0.09%	129
2016 Q4	$215K	Sell	4,456 -616	-12%	-$30.4K	0.09%	142
2016 Q3	$273K	Buy	5,072 +80	+2%	+$4.39K	0.15%	106
2016 Q2	$270K	Buy	+4,992	New	+$263K	0.16%	114
2016 Q1	–	Sell	-5,276	Closed	-$266K	–	103
2015 Q4	$266K	Buy	+5,276	New	+$269K	0.3%	107

Other funds holding GSK

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

FVWA

Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return

SIS

Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return

KFP

Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

Transmarket Holdings Chicago, Illinois $136M AUM

CWA Asset Management Group's GSK Position: Q2 2026 in Review

CWA Asset Management Group increased its GSK (GSK) stake by 13% in Q2 2026, buying an estimated $322K and bringing the position to 53,030 shares worth $2.78M. The position accounts for 0.08% of the portfolio, ranked #227.

CWA Asset Management Group first reported a position in GSK in Q4 2015 and has held it in 36 quarters since. 296 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

CWA Asset Management Group held 53,030 shares of GSK worth $2.78M as of Q2 2026.
CWA Asset Management Group bought 6,089 GSK shares in Q2 2026, an estimated $322K.
GSK made up 0.08% of CWA Asset Management Group's portfolio in Q2 2026, its #227 holding.
CWA Asset Management Group first reported a position in GSK in Q4 2015 and has held it in 36 quarters since.
296 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on CWA Asset Management Group's 13F filing for Q2 2026, filed 14 Jul 2026.